Bank of New York Mellon
MAZE

Bank of New York Mellon’s Maze Therapeutics MAZE Stock Holding History

Bank of New York Mellon’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.91M Buy
97,588
+23,320
+31% +$611K ﹤0.01% 2735
2026
Q1 		$2.22M Buy
74,268
+13,832
+23% +$610K ﹤0.01% 2755
2025
Q4 		$2.5M Buy
60,436
+15,196
+34% +$522K ﹤0.01% 2718
2025
Q3 		$1.17M Buy
45,240
+23,694
+110% +$400K ﹤0.01% 3117
2025
Q2 		$264K Buy
21,546
+4,313
+25% +$44.9K ﹤0.01% 3858
2025
Q1 		$190K Buy
+17,233
New +$207K ﹤0.01% 3898

Other funds holding MAZE

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
MGB
Mass General Brigham Somerville, Massachusetts $361M AUM
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Bank of New York Mellon's MAZE Position: Q2 2026 in Review

Bank of New York Mellon increased its Maze Therapeutics (MAZE) stake by 31% in Q2 2026, buying an estimated $611K and bringing the position to 97,588 shares worth $2.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

Bank of New York Mellon first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 57 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Bank of New York Mellon held 97,588 shares of Maze Therapeutics worth $2.91M as of Q2 2026.
  • Bank of New York Mellon bought 23,320 Maze Therapeutics shares in Q2 2026, an estimated $611K.
  • Maze Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2735 holding.
  • Bank of New York Mellon first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 57 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.